Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TECH
BuyPremium GrowerBio-Techne Corporation · Healthcare · United States · $11.3B · Avg Vol: $199M/d
COMPANY DESCRIPTION
Bio-Techne Corporation provides high-quality purified proteins, antibodies, immunoassays, and instrumentation essential for life science research and clinical diagnostics worldwide. The company's competitive moat is built on its deep scientific expertise and comprehensive portfolio of specialized reagents and instruments, fostering high customer loyalty among researchers and pharmaceutical firms. Bio-Techne is a key enabling partner in drug discovery, diagnostics, and cell & gene therapy development.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.1B | 1.1B | 1.2B | 1.2B | 3.3% | 1.2B | 1.2B | 1.3B | 2.9% |
| EPS | 1.73 | 1.81 | 1.07 | 0.47 | -35.3% | 1.16 | 0.49 | 0.72 | 15.3% |
| Shares | 156.6M | 157.6M | 158.2M | 155.0M | -1.1% | 156.8M | — | — | — |
| Debt | 326.0M | 455.0M | 419.5M | 444.1M | 10.9% | 289.1M | — | — | — |
| Equity | 1.7B | 2.0B | 2.1B | 1.9B | 4.1% | — | — | — | — |
| Op CF | 325.3M | 254.4M | 299.0M | 287.6M | -4.0% | 292.1M | — | — | — |
| Inv CF | -96.9M | -265.6M | -203.0M | -35.2M | — | — | — | — | — |
| Fin CF | -242.9M | 22.6M | -122.4M | -253.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TECH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TECH | Bio-Techne Corporation(you) | $11.3B | 76 | Buy |
| KRYS | Krystal Biotech, Inc. | $10.4B | 74 | Buy |
| CORT | Corcept Therapeutics Incorporated | $12.3B | 71 | Buy |
| BMRN | BioMarin Pharmaceutical Inc. | $12.5B | 63 | Hold |
| HALO | Halozyme Therapeutics, Inc. | $12.0B | 95 | Strong Buy |
| LGND | Ligand Pharmaceuticals Incorporated | $5.6B | 67 | Buy |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.0B | 83 | Strong Buy |
| CAI | Caris Life Sciences, Inc. | $7.2B | 60 | Hold |
| TGTX | TG Therapeutics, Inc. | $8.3B | 57 | Hold |
| EXEL | Exelixis, Inc. | $13.5B | 99 | Strong Buy |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.1%